Technology

A C1 platform oriented toward SAF-relevant intermediates and lipids.

C1 Foundry is exploring biological and process pathways that convert CO2 and related C1 inputs into molecules that can serve SAF supply chains, while preserving broader platform options over time.

Commercial anchor

The current technology focus is SAF feedstocks, not a claim to solve every end market at once.

The platform remains a C1 carbon utilization and metabolic engineering effort, but the near-term technical question is narrower: which biological and process routes can produce intermediates and lipids relevant to SAF supply chains under realistic process constraints. That keeps the work tied to a specific commercialization path rather than a generic platform story.

The key issue is not whether a pathway exists in principle. It is whether carbon flow, reducing power, productivity, and downstream handling can support a credible feedstock business.

C1 inputs

CO2 and related C1 inputs are attractive starting points, but they come with real operating penalties.

Relevant inputs include carbon dioxide, formate, methanol, and other low-complexity carbon streams. They are strategically attractive because of carbon sourcing and long-term availability, but they impose hard constraints around uptake, redox balance, gas handling, safety, and conversion efficiency.

Different inputs change the economics and the biology at the same time. That is why feedstock choice cannot be separated from pathway design or process configuration.

Acetate as intermediate

Acetate may be a useful intermediate when direct conversion is too constrained.

One practical route is to move carbon through acetate rather than force every target product directly from CO2 or another raw C1 input. For SAF-relevant pathways, that can create a more manageable handoff between upstream carbon utilization and downstream lipid production.

Acetate is not automatically optimal. It is useful because it can simplify downstream metabolism while preserving the broader C1 logic of the platform.

Cofeeding logic

Cofeeding matters because carbon supply and energy supply are not the same problem.

A SAF feedstock route may need one stream primarily for carbon and another for energy or reducing equivalents. Cofeeding can make it easier to balance ATP, NADPH, and productivity instead of forcing one molecule to do all the work. That is a practical engineering choice, not a theoretical preference.

The tradeoff is straightforward: more control can also mean more process complexity. The route only works if the added complexity earns its keep economically.

Energy constraints

ATP and NADPH matter because lipid productivity depends on more than carbon stoichiometry.

Many carbon utilization routes look plausible until energy accounting becomes explicit. Cells need ATP for activation and maintenance, and they need reducing power such as NADPH to build reduced products such as lipids. If either is constrained, yield and productivity can fail long before the pathway looks wrong on paper.

For SAF-relevant pathways, carbon balance, redox balance, and energetic burden all affect whether a route can become a credible feedstock option.

Product focus

Lipids are the first commercial focus, but not the only possible platform output.

The near-term product focus is on lipids and related intermediates that can feed existing SAF refining pathways. Over time, the same upstream logic may support terpenoids, specialty molecules, or other product classes. The broader platform matters, but SAF feedstocks are the first wedge because they create a sharper commercialization question.

Technical bottlenecks

The hard parts remain robustness, productivity, and process integration.

Even if a route is chemically sensible, the real bottlenecks may sit in carbon uptake rate, toxicity tolerance, flux control, lipid accumulation, fermentation behavior, or downstream recovery. In early systems, those constraints usually matter more than pathway novelty.

This is why the work has to be treated as a full stack: feedstock handling, metabolism, bioprocess conditions, recovery, and refining fit all affect one another.

Validation

Validation has to answer commercialization questions, not just pathway questions.

The main validation questions are whether targeted routes can sustain meaningful flux into lipids or other SAF-relevant intermediates, whether cofeeding improves the right constraints rather than shifting them, whether acetate helps or hinders the process, and whether the overall system can remain stable under realistic operating conditions.